Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Liabilities and Shareholders Equity: 2016-2019

Historic Liabilities and Shareholders Equity for Monopar Therapeutics (MNPR) over the last 4 years, with Dec 2019 value amounting to $13.4 million.

  • Monopar Therapeutics' Liabilities and Shareholders Equity rose 255.40% to $18.2 million in Q3 2020 from the same period last year, while for Sep 2020 it was $57.1 million, marking a year-over-year increase of 134.46%. This contributed to the annual value of $13.4 million for FY2019, which is 82.46% up from last year.
  • Per Monopar Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $13.4 million for FY2019, which was up 82.46% from $7.3 million recorded in FY2018.
  • In the past 5 years, Monopar Therapeutics' Liabilities and Shareholders Equity ranged from a high of $13.4 million in FY2019 and a low of $2.9 million during FY2016.
  • In the last 3 years, Monopar Therapeutics' Liabilities and Shareholders Equity had a median value of $9.9 million in 2017 and averaged $10.2 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 242.98% in 2017, then declined by 26.31% in 2018.
  • Monopar Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $2.9 million in 2016, then surged by 242.98% to $9.9 million in 2017, then decreased by 26.31% to $7.3 million in 2018, then surged by 82.46% to $13.4 million in 2019.